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Background: Echinocandins are the ﬁrst-line therapy for treatment of invasive Candida
infections, but the mortality rate remains high, calling for novel strategies. Giving single
larger echinocandin doses infrequently is an alternative regimen. Our aim was to test this
novel approach in a neutropenic murine model.
Materials and methods: We compared the in vivo efﬁcacy of single 10 and 40 mg/kg of
caspofungin (2.5× and 10× the normal humanized dose) to that of the same cumulative doses
of daily 2 and 8 mg/kg doses for 5 days against 2 each of wild-type C. albicans and
C. dubliniensis as well as echinocandin resistant C. albicans. As a comparator, we tested
daily 1 mg/kg amphotericin B.
Results: In lethality experiments, all caspofungin and amphotericin B regimens improved
survival against wild-type C. albicans and C. dubliniensis clinical isolates (P<0.0001) and
decreased the mean fungal kidney burdens of both species compared to controls. However,
fungal kidney burden decreases were not always statistically signiﬁcant, especially with
single 10 or 40 mg/kg caspofungin doses. Amphotericin B was the least active drug against
wild-type C. albicans. Against echinocandin-resistant strains, monodose 40 mg/kg caspo-
fungin and 1 mg/kg of daily amphotericin B were effective in lethality experiments.
Although, signiﬁcant kidney CFU decreases were never found, except for amphotericin
B against one of the isolates (p<0.05 at day 3 and p<0.001 at day 6).
Conclusion: Single 40 mg/kg caspofungin and 1 mg/kg amphotericin B proved to be
effective in the lethality experiments against wild-type and echinocandin-resistant
C. albicans and wild-type C. dubliniensis. This was not always shown regarding fungal
tissue burdens. Single caspofungin doses used in mice in this study are attainable in humans
as well, suggesting a potential place of this dosing strategy not only in prevention but also in
curative treatment of evolved invasive Candida infections.
Keywords: humanized caspofungin doses, intermittent dosing regimen of echinocandins,
Candida albicans complex, fungal tissue burden, echinocandin resistance
Introduction
The frequency of invasive Candida infections has increased worldwide in the last
decades. Although the proportion of non-albicans Candida species increased sig-
niﬁcantly, C. albicans is still the most frequently isolated Candida species from
normally sterile body sites.1–5 The mortality rate of invasive Candida infections is
around 40%, but in intensive care units, 50–75% mortality rates were observed
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among critically ill patients even in case of C. albicans
despite the introduction of echinocandins into the antifun-
gal armamentarium.2–4
Echinocandins (caspofungin, micafungin, and anidula-
fungin) inhibit the β-1,3-glucan-synthase in Candida
species.6–8 This antifungal class shows excellent in vitro
and in vivo activity against Candida species and has
quickly become the ﬁrst therapeutic choice for the treat-
ment of candidemia and other forms of invasive Candida
infections.9 Currently, echinocandins are administered as
single daily intravenous doses with minimal side effects.8,9
The unacceptably high mortality rate caused by
Candida infections has inspired physicians to give higher
daily doses to severely ill patients as efﬁcacy of echino-
candins is correlated with AUC/MIC or Cmax/MIC
parameters.6–8,10–14 However, dose escalation studies did
not reveal any advantage in survival rate over the tradi-
tional lower, daily echinocandin doses. Another possible
dosing strategy is using single, large echinocandin doses
infrequently (eg, weekly) with the same cumulative dose
as the daily divided doses.12,14 Such a dosing strategy was
followed only for prophylaxis of esophageal candidiasis
(300 mg micafungin given every other day versus daily
150 mg),12 but clinical data are still lacking as to how the
mortality among patients with disseminated candidiasis is
inﬂuenced by single larger echinocandin doses.
Therefore, the aim of our study was to determine the
in vivo efﬁcacy of single large caspofungin doses one day
post-infection against four C. albicans (including two
echinocandin resistant) and two C. dubliniensis isolates
in a severely neutropenic murine model.
Materials and methods
In vitro studies
Two wild-type C. albicans isolates were derived from blood
samples. Strain 3666 was isolated in 2004 from a 51-year-
old male patient with C. albicans mediastinitis, while strain
2606 was isolated in 2014 from a 1-year-old girl with acute
lymphoid leukemia. Two echinocandin-resistant C. albicans
strains, DPL18 (F641S) and DPL20 (F645P), were isolated
from normally sterile body sites during echinocandins treat-
ment. C. dubliniensis isolates originated from our previous
studies.15 MICs of caspofungin and amphotericin-B (both
from Sigma, Budapest, Hungary) were determined using the
standard CLSI method (M27-A3) in RPMI-1640.16 MIC
values for caspofungin and amphotericin B were read
visually after 24 hrs using the partial and total inhibition
criteria, respectively. C. africana, the third member of the
C. albicans complex was not tested because of its poor
replication ability in vivo, even in a neutropenic murine
model.17 C. parapsilosis ATCC 22019 and C. krusei
ATCC 6258 strains were used as quality control strains.16
All isolates were tested three times.
In vivo studies
Mice and immunosuppression
In the fungal tissue burden experiments BALB/c femalemice
(23–25 g) were given cyclophosphamide 4 days before infec-
tion (150mg/kg), 1 day before infection (100 mg/kg), 2 and 5
days post-infection (100 mg/kg).13,18,19 In the lethality
experiments, this immunosuppression was continued by
administration of 100 mg/kg cyclophosphamide every
third day until the end of the experiment at the 21st day.
The Guidelines for the Care and Use of Laboratory Animals
were strictly followed during maintenance of the animals;
experiments were approved by the Animal Care Committee
of the University of Debrecen (permission no. 12/2014).
Lethality experiments
Mice were assigned randomly to study groups (ten mice/
group) and were infected intravenously through the lateral
tail vein (day 0). The infectious dose for C. albicans and
C. dubliniensis was 2×104 and 2×105 CFU/mouse, respec-
tively, in volumes of 0.2 mL. Inoculum densities were
conﬁrmed by plating serial dilutions on Sabouraud agar
plates.
Treatment with Caspofungin (Cancidas®, commercial
preparation) and amphotericin B (Fungizone®, commer-
cial preparation) began 24 hrs post-infection (day 1).
Both drugs were purchased from our University
Pharmacy and reconstituted according to the recommen-
dation of the manufacturer. In case of wild-type
C. albicans and C. dubliniensis isolates, six treatment
groups were created (no treatment; 1 mg/kg amphoter-
icin B, or 2 or 8 mg/kg caspofungin daily for 5 days;
and the corresponding single caspofungin doses of 10
and 40 mg/kg). Higher single caspofungin doses (60 and
80 mg/kg) led to cca. 80% mortality within 1 day sug-
gesting toxicity of Cancidas®. In case of the echinocan-
din-resistant C. albicans isolates, against which the daily
2 mg/kg for 5 days and its corresponding single
10 mg/kg doses were not effective (100% mortality
within 4 days in preliminary experiments), we used 4
treatment arms (no treatment, 1 mg/kg amphotericin
B daily for 5 days, 8 mg/kg caspofungin daily for
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5 days and the corresponding single dose of 40 mg/kg).
All treatments were given intraperitoneally in a 0.5 mL
volume.
All groups were monitored twice daily for lethality.18
After 21 days, survival rate was analyzed by Kaplan–
Meier test; the effect of different caspofungin doses and
amphotericin B was compared using the logrank test.17–19
Fungal kidney tissue burden experiments
At the beginning of the therapy, fungal kidney burden was
determined after dissection of three untreated mice in case
of each isolate (day 1 control burden). Treatment groups
were assigned as in the lethality experiment, 1 treatment
group included 14–15 mice. The infectious doses for
C. albicans and C. dubliniensis were 104 and 105 CFU/
mouse, respectively.
On day 3 and 6, 7–8 mice were sacriﬁced; both
kidneys from each animal were removed, weighed and
homogenized aseptically in 1 mL of saline and serially
diluted. Fungal tissue burden was determined by quan-
titative culturing. The lower limit of detection was 50
CFU/g of tissue. Kidney burden on day 3 and 6 was
analyzed using the Kruskal–Wallis test with Dunn’s
post-test.17–19
Pharmacokinetics of single 10 and 40 mg/kg
caspofungin in mice
As the relationship of caspofungin doses (administered
once) with AUC0-∞ as well as peak plasma concentration
(Cmax) values is linear in mice,
13 published pharmacoki-
netic data on single 5, 20 and 80 mg/kg caspofungin doses
were used to calculate AUC0-∞ and Cmax values for single
10 and 40 mg/kg caspofungin doses using GraphPad Prism
8.0.1 for Windows (GraphPad Software Inc., La Jolla, CA,
USA) as follows:
(a) y=6.324x+170.7; (r2=0.97),
where y is AUC0-∞ (mg·h/L), and x is the dose of
caspofungin (mg/kg),
(b) y=0.5333x+15.33; (r2=1),
where y is Cmax (mg/L), and x is the caspofungin
dose (mg/kg), with r2=1.
As human single caspofungin doses between 5 and
210 mg also show similar pharmacokinetics,20,21 the single
human doses corresponding to single mouse doses were
determined using mouse AUC0-∞values and the following
equation:
(c) y=1.809x-9.614; (r2=0.9847), where y is AUC0-∞
(mg·h/L) and x is the single caspofungin dose in
human (mg).
Results
MIC results
MIC values for the quality control strains (C. krusei ATCC
6258 and C. parapsilosis 22019 ATCC strains) were
within the published acceptable ranges.16 Caspofungin
MICs for wild-type C. albicans clinical isolates were
within the accepted clinical break-points (Table 1).16
DPL18 and DPL20 C. albicans isolates were resistant to
caspofungin.16 Caspofungin MICs of C. dubliniensis iso-
lates were never higher than the published epidemiological
cut off value for C. dubliniensis (0.125 mg/L) (Table 1).22
Amphotericin B MICs for the six isolates were within the
published ECOFF values (2 mg/L) for the two species.23
Pharmacokinetics of single 10 and 40 mg/
kg caspofungin in mice
Single 10 and 40 mg/kg caspofungin produce 234 and
424 mg·h/L AUC, and 20.7 and 36.7 mg/L Cmax values
in mice, respectively. These AUC values in humans corre-
spond to single 135 mg and 241 mg calculated caspofun-
gin doses, respectively.
Lethality
All caspofungin and amphotericin B regimens improved
the survival in case of the wild-type C. albicans and
C. dubliniensis clinical isolates (P<0.0001, Figure 1).
At day 7, the survival rates were ≥90% for all treatment
arms. However, survival rates decreased to 10–30% and
20–30%, respectively, by day 21 with daily 2 mg/kg and
the corresponding single 10 mg/kg caspofungin doses in
cases of C. albicans isolate 3666 and C. dubliniensis
Table 1 MIC values of caspofungin and amphotericin B against
C. albicans and C. dubliniensis isolates
Isolates MIC (mg/L)
Caspofungin Amphotericin B
C. albicans 3666 0.25 1
C. albicans 2606 0.125 1
C. albicans DPL18 (F641S) 2 0.5
C. albicans DPL20 (F645P) 8 0.5
C. dubliniensis 1081 0.125 0.25
C. dubliniensis 2953 0.125 0.25
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Figure 1 Survival of mice infected with echinocandin-susceptible C. albicans (3666 and 2606), C. dubliniensis (1081 and 2953) and echinocandin-resistant C. albicans (DPL18
and DPL20). The infectious dose for echinocandin-susceptible and echinocandin-resistant C. albicans and echinocandin-susceptible C. dubliniensis were 2×104, 2×104 and
2×105 CFU/mouse, respectively. Intraperitoneal caspofungin and amphotericin B treatment were started 24 hrs after postinfection. After 21 days, the survival rate was
analyzed by Kaplan–Meier test.
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isolate 1081. In contrast, daily 8 mg/kg led to no survival
by day 21, while the corresponding 40 mg/kg single dose
resulted in 100% survival for these two isolates. Single
dose 40 mg/kg was not inferior to the corresponding daily
8 mg/kg in case of the other two echinocandin susceptible
isolates (2606 and 2953) either.
Survival rates of untreated controls at day 7 were lower
in cases of echinocandin-resistant C. albicans isolates
(0–10%) compared to wild-type isolates (20–50%). Daily
8 mg/kg of caspofungin did not improve the survival rates
compared to untreated controls (10–20% within 7 days).
In, contrast single 40 mg/kg caspofungin and 1 mg/kg
amphotericin B increased the survival rates signiﬁcantly
(to 80–100% and to 70–90% at day 7, respectively;
P<0.0001, Figure 1).
Fungal kidney tissue burden
At the beginning of therapy, the mean fungal tissue burden
ranges were 2.6×105–3.1×105, 9.8×104–1.1×105 and 4.8×104–
1.1×105 cells per mouse for wild-type C. albicans, echinocan-
din-resistantC. albicans andwild-typeC. dubliniensis, respec-
tively. Yeasts grew to 1.1–2.8, 1.2–1.4 and 2.8–3.3 log units in
cases of wild-type C. albicans, echinocandin-resistant
C. albicans and wild-type C. dubliniensis, respectively, after
6 days in untreated control mice.
With wild-type C. albicans and C. dubliniensis, all cas-
pofungin treatment arms decreased the mean fungal kidney
burdens compared to controls on day 3 or 6, but the fungal
kidney burden decreases were not always statistically sig-
niﬁcant (Figure 2), especially for single 10 or 40 mg/kg
doses. Fungicidal activity of daily 2 and 8 mg/kg of caspo-
fungin (>3 log decreases) was frequently observed for
C. dubliniensis at day 6. In contrast, with C. dubliniensis
isolate 1081 the fungal tissue burden was higher on days 3
and 6 compared to day 1 burden with single 10 and 40 mg/kg
caspofungin. Amphotericin B treatment yielded higher fun-
gal kidney burdens on day 6 (but not on day 3) in case of
C. albicans than in the case of C. dubliniensis.
Against echinocandin-resistant C. albicans strain
DPL18 (Fks-F641S), single 40 mg/kg caspofungin and
1 mg/kg amphotericin B led to 0.7 and 1.2, and 0.8 and
2.0 log CFU decrease comparing to day 3 and 6 controls,
respectively (Figure 3), of which only amphotericin
B produced signiﬁcant decrease (P<0.05 and 0.001
on day 3 and 6, respectively). Against the DPL20 (Fks-
F645P) isolate daily 8 mg/kg caspofungin, single 40 mg/
kg caspofungin and 1 mg/kg amphotericin B produced
0.08, 0.25 and 0.33 log CFU decrease only on day 6,
respectively (on day 3 no CFU decrease was detected in
any treatment arm), but these were not statistically signiﬁ-
cant (P>0.05 for all doses).
Discussion
Increasing amounts of data suggest that the currently used
standard echinocandin doses (caspofungin: 70 mg loading
dose, then 50 mg daily; anidulafungin: 200-mg loading
dose and then 100 mg daily; or micafungin: 100 mg
daily) may be insufﬁcient to cure invasive Candida infec-
tions among certain severely ill patients.10,11 The standard
echinocandin dosing regimen may result in low echino-
candin exposure in intensive care units, among patients
with obesity, with severe burn injuries and patients with
complicated intra-abdominal infections.24–28 In order to
increase the probability of attaining therapeutic concentra-
tions in infected body sites, several studies experimented
with higher daily doses in treating invasive Candida infec-
tions. However, elevated daily doses of caspofungin and
micafungin did not increase cure rates signiﬁcantly.10,11
Our previous studies in a neutropenic murine model also
conﬁrmed that there were no signiﬁcant differences in
fungal tissue burden decreases between daily 3 mg/kg,
5 mg/kg and 15 or 20 mg/kg caspofungin against
echinocandin-susceptible C. albicans, C. glabrata and
C. krusei, respectively.29–31 Against echinocandin-resistant
C. albicans and C. glabrata even 16 or 20 mg/kg caspo-
fungin were ineffective in reducing the fungal kidneys
burden.19,29,30
Administering single larger echinocandin doses infre-
quently is another therapeutic option compared to divided
smaller daily doses with the same cumulative doses.
Fungal tissue burden experiments showed that single lar-
ger echinocandin doses were not inferior compared to
daily treatment with the same cumulative dose for prophy-
laxis and treatment of invasive candidiases.19,32–35
Moreover, single larger aminocandin (an early echinocan-
din that stuck in phase I clinical trial) doses against
C. albicans postinfection signiﬁcantly increased the survi-
val rates in a disseminated immunocompetent murine
model.35 Infrequently given large doses are the recom-
mended treatment regimen for a next-generation echino-
candin agent, rezafungin (CD101); in phase 3 for
treatment of candidaemia and invasive candidiasis. This
dosing recommendation is based on ﬁndings that infre-
quent larger doses showed better fungal elimination (leth-
ality data were not obtained) than daily doses against
C. albicans.36
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Figure 2 Kidney tissue burden of profoundly neutropenic BALB/c mice infected intravenously with C. albicans 3666, C. albicans 2606, C. dubliniensis 1081 and C. dubliniensis
2953. Fungal kidney tissue burden was determined at day 3 (left panel) and at the end of experiments on day 6 (right panel). Day 1 tissue burden is shown in all graphs for
comparison (Control 1). The bars represent the medians. Burdens of treated mice were compared to burdens of untreated controls measured on the same day of the
experiment (Control 3 and Control 6 in the left and right panels, respectively). Level of statistical signiﬁcance is indicated at P<0.05 (*), P<0.01 (**) and P<0.001 (***).
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In this study in the ﬁrst 7 days, single 10 and 40 mg/
kg caspofungin showed comparable efﬁcacy on survival
rates (90–100%) as the daily, 2 and 8 mg/kg doses
against wild-type C. albicans and C. dubliniensis strains
in a persistently neutropenic murine model. Moreover,
the effect of single 40 mg/kg but not 10 mg/kg caspo-
fungin on survival rate persisted in the next 14 days as
well, increasing the survival rates up to 60–100% for
both species. This dose-dependent effect is not surprising,
as single 40 mg/kg caspofungin produced signiﬁcantly
higher AUC and Cmax values than single 10 mg/kg.
Efﬁcacy of echinocandins best correlates with a free-
drug AUC/MIC (optimal ratio >10–20) or Cmax/MIC
(optimal ratio >1) values.6–9,13,14,37 AUC/MIC value
ranges produced by 10 mg/kg single doses were
32.8–65.5 for wild-type C. albicans and C. dubliniensis
isolates calculating with 3.5% free-caspofungin, while
Cmax/MIC values were 2.9–5.8. In case of single
40 mg/kg caspofungin the free-drug AUC/MIC and
Cmax/MIC values were as high as 59.4–118.7 and
5.2–10.3, respectively. Fungal tissue burdens on day 3
and 6 were concordant with our lethality results at day 7;
all regimens produced at least 1.95 log decrease in day 6
tissue burden. However, in cases of echinocandin-
resistant C. albicans strains, the free-caspofungin AUC/
MIC and Cmax/MIC values even with the 40 mg/kg dose
only were 1.9–7.4 and 0.2–0.6, respectively, predicting
poor outcome in vivo. This was applicable to the fungal
burden data, as the single large dose produced lower
tissue burden decreases, but not for lethality data, where
7-day lethality was comparable, while 21-day lethality
was more favorable in the 40 mg/kg caspofungin arm.
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Figure 3 Kidney tissue burden of profoundly neutropenic BALB/c mice infected intravenously with DPL18 and DPL20 echinocandin-resistant C. albicans isolates. Fungal
kidney tissue burden was determined at day 3 (left panel) and at the end of experiments on day 6 (right panel). Day 1 tissue burden is shown in all graphs for comparison
(Control 1). The bars represent the medians. Burdens of treated mice were compared to burdens of untreated controls measured on the same day of the experiment
(Control 3 and Control 6 in the left and right panels, respectively). Level of statistical signiﬁcance is indicated at P<0.05 (*) and P<0.001 (***).
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This is in line with the widely accepted opinion that
paradoxical growth may be conﬁned to in vitro
situations.10,11,14,32
Similar difference between lethality and fungal burden
results was reported by Najvar et al,35 comparing 5 and
30 mg/kg single-dose caspofungin in immunocompetent
murine bloodstream infection model. Such short-term
therapies as used in animal models of fungal infections
are almost always reported deﬁcient in sterilizing activity;
indicating that for eradication a long-term therapy is
crucial.9,29–31 Interestingly, the calculated pharmacody-
namic parameters predicted the weaker activity on the
fungal burden well, while prognosticated poorly the clin-
ical effect, ie, increased survival.
Similarity of the lethality rates of untreated controls sug-
gests that there are no signiﬁcant differences in virulence
between wild-type and echinocandin-resistant isolates in
bloodstream infection of neutropenic mice. Our ﬁnding is
different from the results by Ben-Ami et al who found that
ﬁtness of the homozygous fks-1 mutant (S645F) strains is
signiﬁcantly lower than for wild-type strain.38 However, they
used non-immunosuppressed BALB/c mice in their experi-
ments. In accordance with the results of Wiederhold et al,39
daily 8 mg/kg of caspofungin at day 7 yielded only 20%
survival rates both for DPL 18 andDPL 20 isolates indicating
that elevated daily doses of caspofungin did not result in
survival beneﬁt compared to untreated controls. In this
study, single 40 mg/kg caspofungin and daily 1 mg/kg of
amphotericin B produced 80–100% and 70–90% survival
against echinocandin-resistant isolates at day 7, respectively.
Moreover, single 40 mg/kg caspofungin prolonged the survi-
val during the next 14 days as well, in spite of the low free-
caspofungin AUC/MIC and Cmax/MIC values.
The possible explanation for the efﬁcacy of single
40 mg/kg of caspofungin against echinocandin-resistant
isolates in the lethality experiments may be related to the
protein-binding. Though in case of caspofungin the percent
of the free fraction among healthy persons is 3.5% this
value could be increased to 7.6% among persons with
invasive Candida infections.37,40 Calculating with 7.6%
free-caspofungin the AUC/MIC and Cmax/MIC values for
isolate DPL18 (MIC=2 mg/L) were 15.9 and 1.38 which are
higher than the recommended 10 and 1 ratios, respectively.
In case of isolate DPL 18, the fungal tissue burden experi-
ments were in accordance with the lethality experiments
(the CFU values were not increased compared to day 1
control; fungistatic effect). However, for isolate DPL20
(MIC=8 mg/L) AUC/MIC and Cmax/MIC were 3.9 and
0.34, respectively, conﬁrming that echinocandin efﬁcacy
is weak in decreasing the fungal tissue burden against iso-
lates very high MICs (ie, 8 mg/L) containing a prominent
FKS1 hot-spot amino acid substitution (S645F). Another
potential explanation is that a dose larger even than loading
doses leads to more rapid increase in tissue drug concentra-
tion, ie, the peak concentration will be higher and reached
faster.14,34,36,37
Notably, survival rates in mice treated with single
40 mg/kg caspofungin were comparable in case of
DPL20 isolate, in case of isolate DPL18 as well as in
case of the echinocandin wild-type isolates.
Results obtained from our mice experiments can be trans-
lated to human as in earlier comparison outcomes in mice
correlated well with treatment success in patients.13,14,41 The
basis for this similarity is that the drug target is within the
organism and is independent of the host; thus, free-drug AUC/
MIC or Cmax/MIC needed for efﬁcacy in a human must be the
same as in a mouse. Single 10 and 40 mg/kg caspofungin
produce 234 and 424 mg·h/L AUCs which correspond to
single 135 and 241 mg caspofungin in humanized doses.
The largest single doses of caspofungin used in healthy volun-
teers were 150 and 210 mg with minimal side effects suggest-
ing that the maximum tolerated human dose still is not
reached.20,21 Inadvertent administration of up to 400 mg of
caspofungin in one day did not result in clinically important
adverse reactions.40 Moreover, daily 200 mg of caspofungin
was well tolerated in phase II dose escalation study for the
treatment of probable aspergillosis.42 Thus, elevated single
dose of caspofungin (ie, 250 or 300 mg) probably can be
used safely for the treatment of invasive Candida infections,
though this assumption awaits conﬁrmation.
In this study, we have found that humanized, single
larger doses of caspofungin showed excellent in vivo efﬁ-
cacy both on the lethality as well as in fungal kidney
burden experiments for the treatment of disseminated can-
didiasis caused by wild-type C. albicans and the closely
related C. dubliniensis in a neutropenic murine model. It is
noteworthy that not only 1 mg/kg of daily amphotericin
B but single 40 mg/kg of caspofungin as well proved to be
effective in survival studies with wild type and echinocan-
din-resistant C. albicans isolates with prominent mutations
in the fks genes. However, this effect was not seen in the
fungal tissue burden experiments. More importantly, single
caspofungin doses for mice used in this study are attain-
able in humans as well, suggesting a potential place of this
dosing strategy not only in prevention but also in treatment
against evolved invasive Candida infections.
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